Daré Bioscience closes $215K Regulation A offering of Series A Preferred Stock and warrants

Dare Bioscience, Inc.

Issued 43,050 Investor Units at $5.00/unit; each unit contains one share of Series A Convertible Preferred and two common stock purchase warrants.
Total gross proceeds of approximately $215,250; warrants exercisable for up to 86,100 shares of common stock.
Offering qualified by SEC on January 5, 2026 under Regulation A; terms previously reported in Form 8-K filed January 29, 2026.
Proceeds provide additional working capital for the company's development programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.